Lantern Pharma (NASDAQ: LTRN) has reported its second-quarter 2026 operational and financial results, showcasing significant progress across its AI-driven oncology pipeline and the creation of Open Medicine AI (OMAI) as a wholly owned subsidiary. The company highlighted emerging data from its Phase 2 HARMONIC trial, which demonstrated that LP-300's progression-free survival benefit deepened with treatment duration in patients with EGFR exon 21 L858R mutations. The U.S. Food and Drug Administration (FDA) reviewed key protocol amendments without objection, potentially paving the way for further clinical development.
In addition to the HARMONIC trial progress, the European Medicines Agency cleared an investigator-initiated Phase 1b/2 trial of LP-184, also known as zirdafulven, in biomarker-selected advanced bladder cancer. Meanwhile, the U.S. Patent and Trademark Office issued a Notice of Allowance for a three-gene patient-selection signature associated with LP-184, which could enhance the precision of patient enrollment in future trials.
A major strategic move was the establishment of OMAI as a separate company in August. Lantern entered into board-approved commercial licensing agreements for its multi-agentic AI co-scientist platform, previously launched as withZeta.ai. This platform is now commercially available as a subscription-based research tool for the global biomedical and drug development community, representing a new revenue stream for Lantern.
Financially, Lantern reported a loss from operations of approximately $3.5 million for the second quarter, a 25% improvement from the $4.7 million loss in the same period last year. Research and development expenses declined by 42% to approximately $1.8 million. The company's net loss was approximately $7.1 million, or $0.57 per share, compared to $4.3 million, or $0.40 per share, in the prior year. The increase in net loss was largely attributed to approximately $3.6 million in warrant-related expenses. As of June 30, 2026, Lantern held cash, cash equivalents, and marketable securities totaling approximately $7.4 million.
Lantern Pharma is a clinical-stage precision oncology company that leverages artificial intelligence, machine learning, and its proprietary RADR platform to transform cancer therapy development. Its clinical pipeline includes LP-184, LP-284, and LP-300. LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, a wholly owned subsidiary. The company operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
The establishment of OMAI and the commercial launch of withZeta.ai could have broader implications for the pharmaceutical industry, as AI-driven drug discovery and development platforms become more accessible. By offering withZeta.ai as a subscription service, Lantern is positioning itself to generate recurring revenue while contributing to the acceleration of biomedical research worldwide.
For more information, visit the full press release at https://nnw.fm/m9pULA.
